HIV/AIDS Drug Pricing & Pharmaceutical Company News
Drug Pricing: Overview
- Overview of Drug Pricing for Public Programs (PDF) (April 2010)
From Project Inform
- The Price Isn't Right (January 25, 2008)
BMS raises HIV/AIDS drug prices, refuses to engage with treatment activists.
In Housing Works AIDS Issues Update, from Housing Works
- Shape-Shifting: The Art of Drug Pricing (October 2007)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Research and Development Costs, Unplugged (May 2004)
[Archived Article]
A chart comparing the R&D costs of five antiretrovirals.
In TAGline, from Treatment Action Group
- Defining the Impact of AIDS Drug Pricing on the Public Sector (May 2004)
Transcript and slides of a talk by Lanny Cross, Program Manager of the New York State AIDS Drug Assistance Program.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Defining the Impact of AIDS Drug Pricing on the Private Sector (May 2004)
Transcript and slides of a talk by Michael Allerton, HIV Operations Policy Coordinator at the Permanente Medical Group.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- An Overview of AIDS Drug Access in the United States (May 2004)
Transcript of a talk by Christine Lubinski, Executive Director of the HIV Medicine Association.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Untangling the Economics of Drug Pricing (May 2004)
Transcript and slides of a talk by Joshua P. Cohen, a senior research fellow at the Tufts Center for the Study of Drug Development.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Paying for Life: The Issues Behind Drug Pricing (Summer 2003)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Glaxo Will Further Cut Prices of AIDS Drugs to Poor Nations (April 28, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Gilead Offers Tenofovir to Developing Countries at Cost (April 4, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Can We Reform the Drug Industry? (April 2002)
An e-mail discussion between an AIDS activist and a patent attorney.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Patient Care Squeezed by Soaring Drug Prices (April 2002)
An in-depth examination of the drug-pricing war raging in the United States.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Drug Pricing: News & Analysis
- Reducing Commodity Costs for ARVs Could Mean Providing Treatment to Millions More People (August 2, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Global Health Partnership Announces First-, Second-Line AIDS Drugs Price Reductions in Developing World (May 18, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Abbott Cuts Cost of AIDS Drug for Government Programs (May 10, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Abbott Cuts Cost of AIDS Drug for Government Programs (April 29, 2011)
In Chicago Tribune
- Gilead Raises Prices of HIV Drugs, AHF Speaks Out Against Price Hike (April 4, 2011)
In Bloomberg Businessweek
- South Africa: How Better ARV Prices Were Won (February 4, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Bloomberg BusinessWeek Explores Growing Trend in Pharma to License, Donate HIV Drugs (August 6, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Can More People Be Put on ART Without Increased Cost? (Summer 2010)
To read PDF, click here.
In TAGline, from Treatment Action Group
- Gilead Adds Discount, Price Freeze for AIDS Drugs (June 14, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- AIDS Healthcare Foundation Keeps Up Pressure in Protests Against Merck's HIV Pricing (April 8, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Study Reveals Cost of "Essential" Antibiotic in Africa (January 14, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Clinton Foundation Reaches Deal With Matrix, Pfizer to Cut Prices for Second-Line ARVs, TB Drug (August 7, 2009)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Federal Appeals Court Rejects Lawsuit Against Abbott Over HIV/AIDS Drug Price Hike (July 8, 2009)
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Abbott Drug Pricing Condemned by AIDS Advocates in International Protests (January 27, 2009)
In coordinated actions, protesters in Mexico, Colombia and the U.S. demand that Abbott lowers the price of its key AIDS drug Kaletra; advocates otherwise vow to seek compulsory licenses in Colombia and Mexico; in U.S., AHF to also premiere 60-second video parody blasting Abbott and CEO Miles White on YouTube and place spot as TV commercial on select Chicago-area television stations.
From AIDS Healthcare Foundation
- GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
If you live in the United States, use private health insurance and take Combivir (AZT/3TC), Epzicom (abacavir/3TC, Kivexa), Lexiva (fosamprenavir, Telzir) or another HIV drug made by GlaxoSmithKline, you may have a chance to save a nice chunk of change.
From GlaxoSmithKline
- Brazil Rejects Patent for Viread (September 5, 2008)
From aidsmap.com
- Three HIV Drug Makers Promise More Help to ADAP and HIVers With Private Insurance (August 1, 2008)
To read PDF, click here.
From Fair Pricing Coalition
- Boehringer, Gilead Freeze Antiretroviral Prices for Some U.S. Agencies (June 5, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Bristol-Myers Slammed By AIDS Group Over Pricing (January 16, 2008)
From Pharmalot
- Isentress (Raltegravir) Pricing: Community Sign-On Letter (October 11, 2007)
In AIDS Treatment News, from AIDS Treatment News
- Student Global AIDS Campaign Responds to Abbott's Decision to Reduce Price of Kaletra in Low and Middle Income Countries (April 10, 2007)
From Student Global AIDS Campaign
- Biotechnology: The Next Frontier for Generic Drugs? (April 7, 2007)
In The New York Times
- Optimal Treatment for 40,000 New HIV Cases in U.S. Will Cost $12 Billion Annually, Study Says (November 2, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Free Trade, Expensive Drugs (Fall 2006)
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
- HIV JournalView: The Rise of Generic Antiretrovirals -- In Developed Countries (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- AIDS Activists Cry Foul as Drug Companies Push Prices to Record Levels (July 9, 2005)
To read PDF, click here.
From AIDS Treatment Activists Coalition
- Medical Innovation Prize Fund: New Idea in Drug Development (June 20, 2005)
A U.S. congressman's plan would allow generic versions of a drug to be sold right after approval.
In AIDS Treatment News, from AIDS Treatment News
- Hundreds of U.S. AIDS Groups Demand Freeze on AIDS Drug Prices (October 15, 2004)
Two hundred AIDS organizations sign the letter, which is directed at seven major drug companies.
From AIDS Treatment Activists Coalition
- How to Ease the Crisis in Drug Pricing (July 2004)
An analysis of several possible solutions to the trend of escalating drug prices in the United States.
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Prominent Medical Group Calls for Full Disclosure on Drug Studies (June 16, 2004)
[Archived Article]
The American Medical Association proposes a national registry to prevent U.S. pharmaceutical companies from hiding negative clinical trial results.
In Boston Globe
- Summary of Highlights From IAPAC Pharmacoeconomics Summit (May 2004)
The one-day summit, held on April 6, 2004, was entitled "Examining the Pharmacoeconomics of U.S. AIDS Drug Access".
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- A Physician's Call to Action: Clinicians Must Act Against Drug Pricing Increases (May 2004)
[Archived Article]
Transcript and slides of a talk by Benjamin Young, M.D., a clinical instructor at the University of Colorado Health Sciences Center.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Critics Decry Escalating HIV/AIDS Drug Prices (January 16, 2004)
In The Washington Blade
- California Legislature Asks Pension Shareholders to Urge Companies to Make AIDS Drugs Affordable, Available in Developing Countries (August 25, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- GlaxoSmithKline Pressed on AIDS Drug Issue (April 16, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Fighting Back Against Pharmaceutical Company Greed (April 2002)
Some global attempts to lower drug prices might work here in the United States.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- PhRMA Speaks! And We All Listen (April 2002)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- You Don't Own Me (February 2002)
The terrible consequences of patents -- not on drugs, but on HIV itself.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Drug Pricing (January 25, 2002)
To read PDF, click here.
In AIDS Treatment News, from AIDS Treatment News
- The Real Cost of Development (July/August 2001)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Who Wants to Be a Millionaire and the Weakest Link (Summer 2001)
Pharmaceutical companies, greed and HIV.
In Women Alive Newsletter, from Women Alive
The Ritonavir (Norvir) Price Increase
- Abbott Agrees to Pay $52 Million in Class Action Suit (April 15, 2011)
In Bloomberg Businessweek
- U.S. Jury Rejects Glaxo Antitrust Claim vs. Abbott (March 31, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Why Abbott Is Allowed to Manipulate GSK and BMS's AIDS Drug Prices (July 8, 2009)
From BNET
- Federal Appeals Court Rejects Lawsuit Against Abbott Laboratories Over Norvir Price Hike (July 7, 2009)
Abbott Laboratories was not taking advantage of its monopoly on HIV "booster" medications to unfairly raise the price of Norvir (ritonavir), a U.S. federal appeals court has ruled.
From Bloomberg.com
- Abbott Agrees to Settle Lawsuit Over Norvir Price Hike (August 1, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Glaxo Joins Lawsuit Against Abbott Over Price of Norvir (November 12, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Pharmacies, Drug Wholesaler File Lawsuit Against Abbott Over Norvir Price (October 30, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Wall Street Journal Examines Reason Abbott Increased Price of Antiretroviral Norvir (January 3, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Aetna Files Lawsuit Against Abbott Over 400% Price Increase of Ritonavir (May 27, 2004)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- U.S. Government Holds Hearing on Generic Production of Ritonavir (May 26, 2004)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Cruising With Lazarus: Abbott Laboratories' Pricing Malfunction (May/June 2004)
[Archived Article]
In Survival News, from AIDS Survival Project
- Abbott's Norvir Price Hike Is Bad Medicine (May/June 2004)
[Archived Article]
Bob Huff explains why the December 2003 ritonavir price increase may well doom the development of boosted protease inhibitors.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- AIDS Advocates, Religious Groups Protest Norvir Price Increase at Abbott Shareholders' Meeting (April 27, 2004)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Two HIV-Infected Patients File U.S. Antitrust Suit Against Ritonavir Price Hike (April 20, 2004)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Hearing on Drug Reimportation to Include Discussion of Abbott's Pricing of Antiretroviral Norvir (April 14, 2004)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Viewpoints
- Pharmaceutical Companies' Profit Protection Hurts Global AIDS Fight (July 27, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- The Fair Pricing Coalition Expresses Dismay at the Price of Merck's Newly Approved Hepatitis C Drug (May 17, 2011)
From Fair Pricing Coalition
- Brazil's Threat to Break Antiretroviral Patents Harms Global AIDS Research, Treatment, Chicago Tribune Says (July 6, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Tangle of Interests and Disclosure Omissions Cracks Authors' Case for Early, Aggressive Treatment (January 2005)
[Archived Article]
AIDS advocate Mike Barr expresses concern over the influence of drug company money on HIV clinical practice -- and over some journals' lax disclosure policies.
In TAGline, from Treatment Action Group
- "On the Take" Explores Money, Medicine and Corruption (October 10, 2004)
Former New England Journal of Medicine editor Jerome P. Kassirer's new book deeply criticizes the influence of pharmaceutical industry money on medicine.
In The Boston Globe
- Veteran NEJM Editor Takes on Big Pharma as No One Before; Calls for Sweeping Reforms (September 2004)
Dr. Marcia Angell's new book blisteringly critiques the pharmaceutical industry.
In TAGline, from Treatment Action Group
- Allow Imported HIV/AIDS Drugs (April 23, 2004)
An op-ed article by Mubarak Dahir, editor of the Express Gay News in Fort Lauderdale, Fla.
In Washington Blade
- Opinion: The Looming Crisis in Drug Pricing (April 2002)
[Archived Article]
Project Inform's Martin Delaney says it's time to draw a line in the sand.
In GMHC Treatment Issues, from Gay Men's Health Crisis
|
Advertisement
|
Email
Glossary
